Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent

(Cancer Research UK) Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 percent, according to the results of one of the largest ever clinical trials for prostate cancer.